OBJECTIVE To comprehensively analyze the effectiveness， safety and economic value of carfilzomib in the treatment of multiple myeloma （MM）， and provide evidence-based guidance for clinical rational drug use. METHODS A systematic search was performed in PubMed， Embase， the Cochrane Library， Web of Science， CNKI， Wanfang， VIP， and relevant health technology assessment （HTA） websites， from database inception to December 31， 2024. Two researchers independently screened studies based on predefined inclusion and exclusion criteria， extracted data， and assessed study quality. Descriptive statistical analyses were conducted. RESULTS A total of 21 studies were included， comprising 7 systematic reviews/meta-analyses， 5 clinical trials， 5 pharmacoeconomic studies， and 4 HTA reports. Effectiveness analysis indicated that， compared with control groups， carfilzomib significantly improved overall response rate and clinical benefit rate （ P ＜0.05）， prolonged progression-free survival， and enhanced patient’s quality of life （ P ＜0.05）， while its impact on overall survival remains to be further confirmed. Safety analysis showed there was no significant difference in the risk of peripheral neuropathy between carfilzomib and controls， while the risks of cardiotoxicity and hypertension were significantly increased （ P ＜0.05）. Economic analysis suggested that carfilzomib regimens demonstrated certain cost-effectiveness in second-line treatment in the U.S. and some European countries. However， its economic value was influenced by drug price， dosing regimen， and regional differences， and it may lack a cost advantage in some countries or in third-line treatment. CONCLUSIONS Carfilzomib shows definite efficacy and generally acceptable safety in the treatment of MM， but cardiotoxicity and hypertension risks require careful monitoring. Given its high treatment cost， pharmacoeconomic studies in the Chinese population are urgently needed.

To address the challenges of capturing micro-strains in detecting esophageal motility disorders and the limitations of existing high-resolution manometry and functional intraluminal imaging probes in directly measuring esophageal tissue electrical impedance, this study proposes a novel flexible balloon sensor structure that integrates a piezoelectric film assembly with a distributed impedance electrode array. Using the electrical analysis module in the finite element analysis (FEA) software, simulations of the forward problem for esophageal impedance detection were conducted to optimize the excitation source parameters, and a physical prototype was fabricated. Under a relative excitation mode with a voltage sensitivity of 2.059%, the voltage output characteristics of the impedance electrode array were analyzed during linear changes in the balloon filling volume. Based on the performance variation of the piezoelectric film assembly, 80% was selected as the optimal filling volume. Force-electric coupling tests were conducted on the balloon sensor using a pressure testing platform, revealing that both the piezoelectric film assembly inside the balloon and the impedance electrodes outside the balloon exhibited significant load differentiation characteristics as the force application point shifted. In summary, this balloon sensor facilitates the localization of force application while simultaneously analyzing esophageal tissue properties, offering a novel diagnostic approach and objective tool for esophageal disease detection.
Esophagus/physiology* ; Electric Impedance ; Humans ; Finite Element Analysis ; Manometry/methods* ; Electrodes ; Esophageal Motility Disorders/physiopathology* ; Equipment Design

Objective:To summarize the early clinical outcomes of aortic valve replacement(AVR) using the Perceval sutureless aortic valve.Methods:This retrospective study included 50 patients who underwent AVR with the Perceval sutureless prostheses at Beijing Anzhen Hospital between June 2023 and January 2025. Surgical parameters, early clinical outcomes, valve function, and hemodynamic performance were evaluated to summarize clinical effectiveness.Results:The mean age of patients was(63.5±9.1) years, predominantly female(36/50). Severe aortic stenosis was present in 43 cases(86.0%). A preoperative aortic annulus dimension of 20.0(19.0, 21.0) mm measured in both anteroposterior and transverse diameters. Preoperative peak transvalvular gradient was(92.7±31.0)mmHg(1 mmHg=0.133 kPa), with a mean gradient of (58.0±21.2) mmHg. All procedures were successfully completed using the Perceval sutureless prostheses. Isolated AVR was performed in 20 patients(40.0%), with cardiopulmonary bypass and aortic cross-clamp times of 75.0(50.5, 99.5) min and 50.5(29.5, 71.5) min, respectively. Postoperative transesophageal echocardiography revealed an immediate reduction in the peak transvalvular gradient to 11.0(8.0, 18.0) mmHg, significantly lower compared to preoperative measurements( P<0.001). Two cases of paravalvular leakage and one case requiring permanent pacemaker implantation were reported postoperatively. All patients completed the 3-month follow-up, with one death during the follow-up period; the remaining patients exhibited normal prosthetic valve function without major adverse cardiovascular events. Significant postoperative reductions were observed in left ventricular end-diastolic diameter(45.8 mm vs. 43.2 mm, P=0.003) and left atrial diameter(53.9 mm vs. 44.6 mm, P<0.001) compared with baseline. Conclusion:AVR using the Perceval sutureless prostheses demonstrated safe and effective early clinical outcomes with excellent hemodynamic performance and low incidence of postoperative paravalvular leakage and permanent pacemaker implantation. The sutureless technique represents a viable alternative strategy, particularly advantageous for patients with small aortic annuli or complex surgical conditions, warranting broader clinical adoption.

Objective To explore the clinical effect of Xuanyunyihao formula on patients with phlegm-dampness obstruction type of vertigo.Methods A total of 80 patients with phlegm-dampness obstruction type of vertigo treated at Jiangxi Hospital of Integrated Traditional Chinese and Western Medicine from July 2023 to March 2025.Participants were divided into control group(n=40)and observation group(n=40)using a random number table.The patients of control group received standard Western medical treatment,while the patients of observation group additionally received Xuanyunyihao formula.Both groups underwent continuous treatment for 14 days.The clinical efficacy,traditional chinese medicine(TCM)syndrome scores,nystagmus electro-oculogram(EOG)positive rates,and adverse reaction incidence were compared between two groups.Results The total effective rate of treatment in observation group was higher than that in control group,and the positive rate of EOG was lower than that in the control group(P＜0.05).Compared with control group,the TCM syndrome score of observation group was lower after treatment(P＜0.05).Conclusion Xuanyunyihao formula has a good effect on dizziness patients with phlegm-dampness obstruction type of vertigo,which is helpful to improve the clinical symptoms of patients,reduce the positive rate of EOG,and has good safety.

The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.

The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.

The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.

Objective:To explore the feasibility and safety of the combined liver and kidney procurement technique with preservation of the donor diaphragm.Methods:A retrospective study was conducted on the clinical data of 135 donors with pulmonary infection who underwent combined liver and kidney procurement and their corresponding 370 recipients in the Department of Transplantation, Guangxi Zhuang Autonomous Region People's Hospital from January 2021 to August 2023. According to whether the donor diaphragm was resected during procurement, the donors were divided into diaphragm preservation group (67 cases) and diaphragm resection group (68 cases). The t-test and chi-square test were used to compare the baseline characteristics of the donors, donor procurement time, surgical injury to organs, donor-derived infection (DDI), delayed graft function (DGF), primary non-function (PNF), and perioperative death between the two groups.Results:There were no statistically significant differences in age, sex, body mass index, number of organs procured, number of organs transplanted, number of organs discarded, or positive rate of sputum cultures for different strains between the two groups (all P>0.05). The donor procurement time was (46.70±12.61) min in the diaphragm preservation group and (45.79±12.78) min in the diaphragm resection group, with no statistically significant difference ( P=0.679). No surgical injuries to other abdominal organs (such as intestines or, in the diaphragm resection group, the lungs) occurred during procurement. After transplantation, the incidence of delayed graft function in kidney recipients was 7.32% (9/123) in the diaphragm preservation group and 11.67% (14/120) in the diaphragm resection group, with no statistically significant difference between the two groups ( P=0.279). The incidence of DDI was 0 in the diaphragm preservation group and 7.07% (13/184) in the diaphragm resection group, showing a statistically significant difference ( P<0.001). No cases of primary non-function or perioperative death occurred in either group. Conclusion:Compared with the conventional method, the combined liver and kidney procurement technique that preserves the donor diaphragm does not significantly increase operative time, organ injury, delayed graft function, primary non-function, or perioperative mortality. It significantly reduces the incidence of donor-derived infections and is worthy of clinical promotion and application.

To summarize and analyze the clinical data of one case of kidney transplantation in an HIV-positive child with end-stage renal disease (ESRD) in the Department of Transplantation, the People's Hospital of Guangxi Zhuang Autonomous Region, and to explore the safety and efficacy of kidney transplantation in HIV-positive children with ESRD. This pediatric recipient was found to be HIV-positive at birth and underwent kidney transplantation due to ESRD, with good postoperative recovery. During the 2.5-year follow-up, no rejection or rebound in HIV RNA levels was observed. The function of the transplanted kidney was good, and the quality of life was comparable to that of healthy individuals. It suggests that kidney transplantation in HIV-positive children with ESRD is safe and effective under adequate preoperative preparation and close postoperative follow-up.

BACKGROUND:Traditional therapies for temporomandibular joint disorders are limited by the severity of the condition and individual differences.In contrast,tissue engineering,as an emerging therapeutic approach,offers personalized treatment options tailored to the specific needs of patients,reducing uncertainties during surgical procedures,and enhancing clinical outcomes.OBJECTIVE:To summarize the latest research achievements and advancements in tissue engineering for temporomandibular joint repair.METHODS:Literature searches were conducted on PubMed and China National Knowledge Infrastructure(CNKI)databases using the Chinese and English search terms"temporomandibular joint,tissue engineering,seed cell,scaffold,growth factor,animal model."The search period covered the inception of each database up to March 2024.Literature screening was performed by analyzing and reviewing relevant articles according to exclusion criteria,ultimately including 57 articles for review.RESULTS AND CONCLUSION:(1)With advancements in biology,materials science,and engineering,significant progress has been made in temporomandibular joint tissue engineering,including the selection of seed cells,development of novel scaffolds,exploration of growth factor mechanisms,and construction of various animal models.Most studies are still in the in vitro experimental stage,and in vivo studies such as animal experiments are not yet widely conducted.The clinical application of tissue engineering in repairing the temporomandibular joint requires more evidence.(2)Despite the remaining challenges and issues to be addressed in temporomandibular joint tissue engineering research,it still presents vast clinical application prospects and is poised to become an excellent and efficient treatment modality for temporomandibular joint disorders in the future.